To include your compound in the COVID-19 Resource Center, submit it here.
Oxford BioMedica said the Velindre Cancer Centre began the open-label, U.K. Phase II SKOPOS trial
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury